Butamirate citrate is a widely used non-narcotic antitussive agent that has gained significant popularity in many parts of the world, particularly in Europe and Asia, as an effective cough suppressant. This article provides a thorough examination of its properties, mechanisms, clinical applications, and safety considerations to enhance understanding of this important pharmaceutical agent.
Introduction
Butamirate citrate (also known as butamyrate citrate) is a non-narcotic antitussive medication primarily used for the symptomatic treatment of non-productive cough. Unlike codeine and other opioid-based cough suppressants, butamirate is not chemically or pharmacologically related to opioid alkaloids, making it an attractive alternative for cough management.
This distinct pharmacological profile provides important advantages as it does not produce the undesirable effects typically associated with narcotic antitussives, such as sedation, constipation, and addiction potential.
The medication is available in various pharmaceutical formulations including tablets, syrups, lozenges, dragées, and oral drops, providing flexible dosing options for different patient populations ranging from infants to elderly adults. Butamirate has demonstrated effectiveness in managing both acute and chronic coughs, particularly beneficial for patients suffering from respiratory conditions where cough suppression is necessary.
Chemical Structure
Butamirate has the chemical name 2-phenylbutyric acid 2-[2-(diethylamino)ethoxy]ethyl ester. The molecular formula for butamirate is C18H29NO3 with a molecular weight of 307.43 g/mol, while butamirate citrate (C18H29NO3·C6H8O7) has a molecular weight of 499.55 g/mol.
Structurally, butamirate belongs to a class of 2-(2-diethylaminoethoxy)ethyl esters and is chemically related to other antitussive agents such as oxeladin and pentoxyverine. It is characterized as a non-narcotic substance that exerts antitussive effects through mechanisms distinct from those of opioid-based cough suppressants.
Butamirate-Based Medicines
Below are eight prominent butamirate-containing medications marketed globally:
- Sinecod: One of the most widely distributed brands, manufactured by various companies including GlaxoSmithKline and Novartis, available in multiple formulations across Europe, Asia, and Latin America.
- Panatus/Panatus Forte: Manufactured by Krka and available in several Eastern European countries including Lithuania and Bosnia & Herzegovina.
- Omnitus: Produced by Hemofarm and distributed in Bosnia & Herzegovina, Macedonia, Russian Federation, and Serbia.
- Butamirato Mylan Generics: A generic version available in Italy.
- Stoptussin: A combination product containing butamirate and guaifenesin, manufactured by Teva and available in Czech Republic, Slovakia, Latvia, and Lithuania.
- Supremin: Produced by Pliva in Croatia and Teva Pharmaceuticals in Poland.
- Buticod: Manufactured by Lloyd Laboratories in the Philippines, available as a 7.5 mg/5 mL syrup.
- Butagan: Available as a 7.5 mg/5 mL syrup produced by ANFARM HELLAS S.A..
Mechanism of Action
Butamirate citrate exhibits a multi-faceted mechanism of action that explains its effectiveness in cough suppression:
Central Mechanism
Butamirate acts centrally by diminishing the tussigenic (cough-inducing) reflex through its effect on the cough center in the medulla oblongata of the brain. Research has found that it binds to the cough center, specifically the dextromethorphan-binding site in guinea pig brain with high affinity. This central action suppresses the cough reflex without causing the significant sedation or respiratory depression associated with opioid cough suppressants.
Peripheral Mechanism
In addition to its central effects, butamirate demonstrates peripheral activity through bronchospasmolytic (bronchodilatory) properties. This helps relax bronchial smooth muscles, reducing bronchoconstriction and making breathing easier.
The peripheral action is further enhanced by anti-inflammatory properties that help reduce inflammation in the respiratory tract. This dual central and peripheral mechanism explains the comprehensive cough-suppressing effect observed clinically.
Unlike opioid antitussives, butamirate does not bind to mu-opioid receptors, which explains its favorable side effect profile and lack of addiction potential. This distinct mechanism makes it particularly valuable for patients who cannot tolerate or should avoid opioid-containing medications.
Pharmacokinetics
The pharmacokinetic profile of butamirate citrate contributes significantly to its clinical utility:
Absorption
When administered orally, butamirate is absorbed rapidly and completely from the gastrointestinal tract. This contributes to its relatively quick onset of action, with some formulations beginning to work within 5 minutes of administration.
Distribution
Butamirate and its metabolites are extensively bound to plasma proteins (approximately 95%), which contributes to their longer half-life and duration of action. The medication is widely distributed throughout the body, including respiratory tissues where it exerts its therapeutic effects.
Metabolism
Hydrolysis of butamirate begins in the plasma, primarily converting it to 2-phenylbutyric acid and diethylaminoethoxyethanol. Interestingly, both of these metabolites also possess antitussive properties, potentially prolonging the therapeutic effect.
The peak plasma level of 2-phenylbutyric acid reaches approximately 6.4 µg/mL following administration of 150 mg butamirate citrate, typically occurring at around 1.5 hours post-administration.
Elimination
The apparent elimination half-life is approximately 6 hours. The three metabolites are predominantly eliminated through renal excretion (90%), with the acid metabolites typically conjugated with glucuronic acid prior to elimination. The pharmacokinetic behavior shows linearity following repeated administration with no significant accumulation observed with regular dosing.
Therapeutic Uses
| Therapeutic Application | Clinical Context | Duration |
|---|---|---|
| Dry, non-productive cough | Primary indication for use; particularly effective for irritation-based coughs | Short-term symptomatic relief |
| Cough due to respiratory infections | Provides relief from persistent coughing associated with viral or seasonal respiratory illnesses | Until symptoms resolve (typically 4-7 days) |
| Irritable cough | Reduces severity and frequency of coughing episodes in patients with irritable cough conditions | Based on symptomatic period |
| Nocturnal cough | Helps improve sleep quality by reducing nighttime coughing episodes | Nighttime use as needed |
| Post-viral cough | Effective in managing lingering cough following respiratory infections | Until resolution of post-viral syndrome |
| Cough in geriatric patients | Demonstrated efficacy in elderly patients with various lung conditions | Based on individual response and condition |
Side Effects
Although butamirate citrate is generally well-tolerated, it can cause certain adverse effects. Most side effects are rare (occurring in fewer than 1 in 1,000 patients) and typically mild in nature:
Nervous System Effects
Patients may experience somnolence (drowsiness) and dizziness, which can potentially affect daily activities. These effects are typically transient and resolve with continued use or discontinuation of the medication.
Gastrointestinal Effects
Gastrointestinal disturbances include nausea, diarrhea, vomiting (particularly in cases of overdose), and general stomach discomfort. These symptoms are usually self-limiting and tend to resolve spontaneously in most cases.
Cutaneous Effects
Skin-related side effects can include itchy skin rashes and urticaria (hives), which may indicate a hypersensitivity reaction to the medication. If such reactions occur, medical attention should be sought promptly.
Cardiovascular Effects
In cases of overdose, hypotension (low blood pressure) may occur along with intensified versions of the above symptoms. This underscores the importance of adhering to recommended dosages.
Drug Interactions
Butamirate has a relatively favorable interaction profile, though several important considerations should be noted:
Expectorants
The most significant contraindication is the concurrent use of expectorants (drugs that aid in clearing mucus from the airways). Since butamirate suppresses the cough reflex, combining it with expectorants could lead to accumulation of bronchial secretions, increasing the risk of bronchospasm and respiratory tract infections.
Enzyme Inhibitors
Although specific metabolic pathways haven’t been fully elucidated, butamirate should not be used together with strong enzyme inhibitors due to the possible risk of increased exposure. This suggests potential involvement of metabolic enzymes such as cytochrome P450 in butamirate elimination.
Drugs with Narrow Therapeutic Index
Medications with a narrow therapeutic index (small difference between effective and toxic doses) should not be used concurrently with butamirate due to potential altered exposure to these drugs. This precaution is largely theoretical, as there is limited data on butamirate’s potential to affect the pharmacokinetics of other medications.
Beyond these specific concerns, no other clinically significant drug interactions have been reported in the available literature.
Safety Considerations
Several important safety considerations should guide the appropriate use of butamirate citrate:
Pregnancy and Breastfeeding
Butamirate is not recommended during the first trimester of pregnancy due to insufficient safety data. During the second and third trimesters, it should be used only when absolutely necessary after careful consideration of benefits versus risks. Additionally, butamirate is not recommended during breastfeeding as there is no data available regarding its excretion in breast milk.
Pediatric Use
The use of butamirate in very young children requires caution. Some formulations specify that they should not be used in children under 3 years of age without medical supervision. Different formulations have specific dosing recommendations based on age groups, highlighting the importance of selecting the appropriate formulation for pediatric patients.
Renal and Hepatic Impairment
Limited information is available regarding the use of butamirate in patients with kidney or liver dysfunction. Patients with renal and/or hepatic impairment may be at greater risk for adverse effects due to potential accumulation of the drug or its metabolites. Closer monitoring may be warranted in these populations.
Driving and Operating Machinery
Butamirate may cause drowsiness and dizziness in some individuals, potentially impairing the ability to drive or operate machinery safely. Patients should be advised to exercise caution when performing activities requiring mental alertness until their individual response to the medication is known.
Duration of Treatment
Treatment should be limited to the symptomatic period, generally not exceeding 7 days without medical consultation. Medical advice should be sought if the cough persists for more than 4-5 days, or if symptoms such as fever, dyspnea (difficulty breathing), or persistent headache develop.
Regulatory Status
The regulatory status of butamirate citrate varies considerably across different regions worldwide:
Butamirate citrate is approved and widely used in many European countries, where it has been a trusted antitussive agent for decades. It is also commonly available in various Asian markets, including Bangladesh, Philippines, Taiwan, and Thailand, as well as in several Latin American countries. However, it has not received approval for use in the United States.
Regarding prescription status, butamirate is available as an over-the-counter (OTC) medication in some countries, including the Philippines where it is classified as OTC. In other regions, it requires a prescription, particularly for certain formulations or age groups.
For pediatric formulations, some countries restrict use in young children without a doctor’s prescription, highlighting the varying regulatory approaches to this medication across different healthcare systems. The registration periods and renewal processes also vary by country, with some approvals extending for five years or more.
Conclusion
Butamirate citrate represents an important therapeutic option in the management of cough, particularly for patients who require an effective alternative to opioid-based antitussives. Its non-narcotic nature, combined with a dual mechanism of action targeting both central and peripheral pathways, makes it an effective and generally well-tolerated medication for symptomatic relief of dry, non-productive cough.
The favorable safety profile of butamirate citrate, characterized by rare and typically mild adverse effects, minimal drug interactions, and absence of addiction potential, positions it as a valuable alternative to traditional cough suppressants. However, clinicians should remain mindful of appropriate patient selection, adherence to recommended dosing guidelines, and awareness of potential precautions-particularly regarding concomitant use with expectorants and use in special populations such as pregnant women.
While butamirate citrate has gained widespread acceptance in many parts of the world, ongoing research and clinical experience continue to refine our understanding of its optimal use in cough management across different patient populations.
